Detection of immunoreactive p53 protein in the stool of patients with colorectal cancer;Detection de la proteine p53 dans les selles de malades atteints de cancer colo-rectal

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 10, 1997, Pages 754-759

  Jaïs, Philippe ^a   Kapel, Nathalie ^b   Chosidow, Denis ^a   Rupaire, Nadine ^a   Rougier, Philippe ^c   Lasser, Philippe ^c   Mignon, Michel ^a   Lewin, Miguel J M ^a   Gobert, Jean Gérard ^b  

^a BICHAT HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Colorectal cancer; ELISA; Hemoccult; P53 protein; Screening

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; RECTUM ADENOMA; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CHEMISTRY; COLORECTAL TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FECES; MIDDLE AGED; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031324407     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Allison J, Tekawa I, Ransom L, Adrain A. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
2. Macrea F, St John D. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982;82:891-8.
3. Mandel J, Bond J, Church T, Snover D, Bradley G, Schuman L, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
4. St John D, Young G, Alexeyeff M, Deacon M, Cuthbertson A, Macrea F, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-8.
5. Jahn H, Joergensen O, Kronborg O, Fenger C. Can hemoccult II, replace colonoscopy in surveillance after radical surgery for colorectal cancer after polypectomy ? Dis Colon Rectum 1992;35:253-6.
6. Griffith C, Turner D, Saunders J. False-negative results of Hemoccult-test in colorectal cancer. BMJ 1981;283:472.
7. Rex D, Lehman G, Ulbright T, Smith J, Pound D, Hawes R et al. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and familly history. Am J Gastroenterol 1993;88:825-31.
8. Ransohoff D, Lang C. Small adenomas detected during fecal occult blood test screening for colorectal cancer: the impact of serendipity. JAMA 1990;264:76-8.
9. Lipkin M, Bell B, Scherlock P. Cell proliferation kinetics in the gastrointestinal tract of man. Cell renewal in colon and rectum. J Clin Invest 1963;42:767-76.
10. Villa E, Dugani A, Rebecchi A, Vignoli A, Grottola A, Buttafoco P et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996;110:1346-53.
11. Sidransky D, Tokino T, Halmilton S, Kinzler K, Levin B, Frost P et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
12. Smith-Ravin J, England J, Talbot I, Bodmer W. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995;36:81-6.
13. Mizuno M, Nakagawa M, Uesu T, Inoue H, Inaba T, Ueki T et al. Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. Gastroenterology 1995;109:826-31.
14. Yuan M, Zhang Y, Leu Y, Tobi M. Sensitivity of fecal ADNAb-9 testing for colorectal neoplasia. Gastroenterology 1996;110:A360.
15. Vogelstein B, Kinzler K. p53 function and dysfunction. Cell 1992;70:523-6.
16. Baker S, Markowitz S, Fearon E, Willson J, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-5.
17. Finlay C, Hinds P, Levine A. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
18. Levine A, Momand J, Finlay C. The p53 tumor-suppressor gene. Nature 1991;351:453-6.
19. Lane D. p53, guardian of the genome. Nature 1992;358:15-6.
20. Rodrigues N, Rowan A, Smith M, Kerr I, Bodmer W, Gannon J et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9.
21. Goh H, Yao J, Smith D. p53 point mutation and survival in colorectal cancer patients. Proc Natl Acad Sci USA 1995;55:5217-21.
22. Fearon E, Vogelstein B. A genetic model for colorectal carcinogenesis. Cell 1990;61:759-67.
23. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain R, Remvikos Y et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
24. Baker S, Preisinger A, Jessup J, Paraskeva C, Markowitz S, Willson J et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal carcinogenesis. Cancer Res 1990;50:7717-22.
25. Soussi T, Legros K, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
26. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half life. Mol Cell Biol 1988;8:531-9.
27. Van Den Berg F, Tigges A, Schipper M, Den Hartog-Jager F, Kroes W, Walboomers J. Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989;157:193-9.
28. Kawasaki Y, Monden T, Morimoto M, Myoshi Y, Kobayashi T. Immunohistochemical study of p53-expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992;97:244-9.
29. Bell S, Scott N, Cross D, Sagar P, Lewis F, Blair G et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
30. Purdie C, O'Grady J, Piris J, Wyllie A, Bird C. p53 expression in colorectal tumors. Am J Pathol 1991;138:807-13.
31. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon R, Dutrillaux B et al. Increased p53 protein content of colorectal tumors correlate with poor survival. Br J Cancer 1992;66:758-64.
32. Laurent-Puig P, Delattre O, Olschwang S, Remvikos Y, Salmon RJ, Frelat G et al. Etude conjointe de la mutation de l'oncogène Ki-ras et de la surexpression de l'oncoprotéine p53 dans les tumeurs colorectales. Gastroenterol Clin Biol 1990;14:347-51.
33. Remvikos Y, Laurent-Puig P, Salmon R, Frelat G, Dutrillaux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 1990;45:450-6.
34. Crawford L, Pim D, Lamb P. The cellular protein p53 in human tumours. J Pathol 1984;2:261-72.
35. Gannon J, Greaves R, Iggo R, Lane D. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-1602.
36. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995;11:763-70.
37. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveal that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994;13:3496-504.
38. McIlwrath A, Vasey P, Ross G, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 of radiosensitivity. Cancer Res 1994;54:3718-22.
39. Morrin M, Kelly M, Barrett N, Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognosis significance. Gut 1994;35:1627-31.
40. Brentall T, Crispin D, Rabinovitch P, Haggitt R, Rubin C, Stevens A et al. Mutations in the p53 gene: an early marker of neopastic progression in ulcerative colitis. Gastroenterology 1994;107:369-78.